-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immunodysfunctional neuropathy and usually occurs
In this EAN/PNS guideline, electrodiagnostic support remains the primary diagnostic requirement for
A retrospective study was conducted on 120 consecutive patients with clinical diagnosis of "suspected CIDP" and objective treatment response who attended the University Hospital of Birmingham in the UK to meet EAN/PNS 2021 criteria
Standardized electrodiagnostic protocol
The median, ulna, fibular and tibial motor nerves, as well as the median, ulnar, radial and sural sensory nerves, are studied
Aggregate allocation of patient groups and standard satisfaction
The sensitivity of the EAN/PNS standard to "CIDP" is 83.
The sensitivity and specificity of the updated version of the EAN/PNS standard to clinical "suspected CIDP" is similar to that of previous versions
There is a lack of reliable diagnostic biomarkers and no alternative diagnostic gold criteria
The updated CIDP diagnostic criteria do not appear to be limited by the reduction in diagnostic categories, nor are they more sensitive or specific than older versions